cukurova medical journal, vol.44, no.4, pp.1379-1385, 2019 (Journal Indexed in ESCI)
Purpose: The aim of this study was to present the survival
analyses of patients with intrahepatic cholangiocellular
carcinoma who are ineligible forsurgical treatment and
treated with transarterial radioembolization.
Materials and Methods: Twenty-eight patients with
intrahepatic cholangiocellular carcinoma who were not
eligible for surgical treatment were included in this study.
All patients were treated by transarterial
radioembolization. The survival time of the patients who
were followed up after diagnosis was recorded. KaplanMeier survival analysis was used to calculate survival.
Results: The mean age was 60.46 years. While minimum
age of patients was 36 years, maximum age of patients 84
years. The median follow-up was 14 months (min:3,
max:33). The median survival time of the patients was 22
months (min:3 months, max:33 months). In addition, the
survival time of patients who received chemotherapy and
patients who did not receive chemotherapy, patients with
solitary tumor, patients with multifocal tumor, patients
with tumor unilobar and patients with bilobar were
calculated and no significant difference was found between
Conclusion: Although modern chemotherapy has
increased this survival rate, it has not been able to increase
the median survival beyond 12 months. When these data
are taken into consideration, it is seen that transarterial
radioembolization treatment prolongs survival.